Oxford BioDynamics part of consortium shortlisted for Strategic Government Initiative to Improve Cancer Immunotherapy

Contributed by: Business Wire

Logo

Tags

Health Insurance

Data Management

Technology

Pharmaceutical

Oncology

Biometrics

General Health

Genetics

Clinical Trials

Other Technology

Science

Biotechnology

Other Science

Health

Research

EpiSwitch CiRT

More Like This

EDX Medical to Market Pioneering Cancer Drugs Response Assay in UK and Nordics

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

GlobeNewswire associated0

4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy

BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA

ACCESSWIRE associated0

New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg

Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395

PR Newswire associated0

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications